Navigation Links
Researchers unfold the mechanisms underlying blood disorders
Date:7/24/2012

A Finnish research team together with researchers from New York, USA, has uncovered a protein structure that regulates cell signalling and the formation of blood cells. The team's results, published in Nature Structural & Molecular Biology, the most prestigious journal in the field, shed light on the mechanisms at play in haematological disorders and provide new opportunities for the design of disease-specific treatment. The work was carried out with funding from the Academy of Finland, the Cancer Society of Finland, National Institutes of Health and the Sigrid Juslius Foundation.

Blood cell formation and activity is regulated by cytokines, small cell-signalling protein molecules, through a signal pathway mediated by Janus kinases (JAKs), a family of enzymes. Previous studies have shown that mutations in JAKs can cause severe haematological disorders as well as immunological diseases. These mutations are concentrated in the pseudokinase domain.

Leading laboratories and pharmaceutical companies around the world have long aimed at defining the structure of the pseudokinase domain of JAKs, as it has been found to be a veritable hotspot for pathogenic mutations causing haematological disorders. Led by Professor Olli Silvennoinen, the Finnish research team has now successfully determined the three-dimensional atomic-level structure of both the normal and the pathogenic pseudokinase domain.

Novel therapeutics

Professor Silvennoinen's team is the first to describe the structure of the pseudokinase domain of JAKs, laying bare the domain's enzymatic mechanisms at the atomic level. The team also managed to determine the structural change, caused by the JAK2 V617F mutation, which gives rise to common myeloproliferative diseases (MPDs), such as polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). PV and ET are blood disorders characterised by an overproduction of red blood cells or platelets, whereas MF is a disorder that causes scar tissue to accumulate in the bone marrow. The team's research results can be put to good use in developing new, targeted therapeutics for these disorders.

The study now published in Nature Structural & Molecular Biology builds on the long-standing expertise of Professor Silvennoinen's team in Janus kinases. In the early 1990s, while working in the US, Silvennoinen successfully cloned the JAK2 gene and demonstrated its activity in the signalling pathways of erythropoietin and interferon. In Finland, the Silvennoinen's work focused on the pseudokinase domain, determining and characterising its regulatory function.


'/>"/>
Contact: Professor Olli Silvennoinen
olli.silvennoinen@uta.fi
358-503-595-740
Academy of Finland
Source:Eurekalert

Related medicine news :

1. New lipid screening guidelines for children overly aggressive, UCSF researchers say
2. BUSM researchers identify genetic markers for testosterone, estrogen level regulation
3. UGA researchers develop rapid diagnostic test for pathogens, contaminants
4. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
5. Researchers link Kawasaki Disease in childhood with increased risk of adult heart disease
6. Researchers to use novel metabolomics technology for COPD
7. Researchers hit back at early bodycheck theory
8. Cleveland Clinic researchers discover molecule that may prevent atherosclerosis
9. Researchers developing new multiple sclerosis drug that can be taken orally
10. UMass Amherst researchers unravel secrets of parasites replication
11. U-M researchers identify new genetic cause for chronic kidney disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Linda, Ca (PRWEB) , ... August 16, 2017 , ... ... innovators, engineers, and scientists from around the world, is excited to announce Andrew Ly ... him in his academic pursuits, covering textbook costs. , Ly, who is in ...
(Date:8/16/2017)... ... 16, 2017 , ... With a new PD diagnosis every nine minutes, research ... The grants are awarded through a competitive application process and reviewed by APDA’s Scientific ... and expertise in all areas relevant to PD research. The SAB meets annually ...
(Date:8/16/2017)... ... August 16, 2017 , ... Melbourne’s reign as the world’s most liveable city ... (EIU) annual Liveability Index. , The Index surveys 140 of the world’s cities and ... Melbourne has consistently come in the top three of the index. So what is ...
(Date:8/16/2017)... Fla. (PRWEB) , ... August 16, 2017 , ... ... and management company based in Vero Beach, announced today that two of their ... an organization that represents professionally managed senior living communities in Florida. The awards ...
(Date:8/16/2017)... City, Utah (PRWEB) , ... August 16, 2017 , ... ... on the Inc 5000 list for the fourth consecutive year. With 197% ... 5000 2017 list of the nation’s fastest growing companies. , Previous honors ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO), is now ... residents. Naloxone is available without a ... pharmacy, G-3320 Beecher Road. ... Administration, is intended to block or reverse the effects ... of consciousness. The medication is often carried by first ...
(Date:8/14/2017)... HACKENSACK, N.J. and PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... for the second quarter ending June 30, 2017. ... advanced stages of preparing for our pivotal Phase 3 ... Chaim Lebovits , President and Chief Executive Officer ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
Breaking Medicine Technology: